SCHEMBL5689574

SCHEMBL5689574

c1ccc(CCCNC2CCC(c3ccccc3)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 12/20 0.65
SIGMAR1 Q99720 7/20 0.65
GRIN1 Q05586 2/20 0.65
OPRM1 P35372 1/20 0.53
OPRL1 P41146 1/20 0.53
SPHK1 Q9NYA1 1/20 0.53
MEN1 O00255 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5689642 1.00 GRIN2B (0.65) GRIN2BSIGMAR1GRIN1OPRM1OPRL1
SCHEMBL5689576 1.00 GRIN2B (0.65) GRIN2BSIGMAR1GRIN1OPRM1OPRL1
SCHEMBL5689946 0.90 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1SPHK1
SCHEMBL5689944 0.90 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1SPHK1
SCHEMBL5690203 0.90 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1SPHK1
SCHEMBL5689596 0.90 GRIN2B (0.57) GRIN2BSIGMAR1GRIN1OPRM1OPRL1
SCHEMBL6836291 0.90 GRIN2B (0.57) GRIN2BSIGMAR1GRIN1SPHK1
SCHEMBL5689598 0.90 GRIN2B (0.57) GRIN2BSIGMAR1GRIN1OPRM1OPRL1
SCHEMBL6836293 0.90 GRIN2B (0.57) GRIN2BSIGMAR1GRIN1SPHK1
Hydrochloric Acid SCHEMBL5691921 0.89 GRIN2B (0.60) GRIN2BSIGMAR1GRIN1OPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed